Viral Vector Manufacturing Market is expected to reach US$ 5.76 Billion by 2031

Rising Patient Safety Demands Fuel Viral Vector Manufacturing Market Growth

According to our latest study, “Viral Vector Manufacturing Market Size and Forecast (2021–2031), Global and Regional Share, Trend, and Growth Opportunity Analysis – by Type, Disease Indication, Application, End User, and Geography," the market was valued at US$ 1.74 billion in 2024 and is expected to reach US$ 5.76 billion by 2031; it is estimated to record a CAGR of 18.8% during 2025–2031. The report includes prospects owing to the current viral vector manufacturing market trends and their foreseeable impact during the forecast period.

The rising prevalence of chronic diseases drives the viral vector manufacturing market growth, as the surging cases of cancer, genetic disorders, and rare diseases highlight the urgent need for advanced gene therapies and targeted treatments. A significant increase in the use of gene and cell therapies in clinical trials—particularly for rare genetic disorders, hematologic malignancies, and neurological diseases—has been observed. These therapies often utilize viral vectors such as adeno-associated virus (AAV), lentivirus, and adenovirus for gene delivery. As more programs move into later phases of development, the demand for viral vectors will grow, in amount and quality, placing increasing demands on capacity for manufacturers to address the growing demand. This article highlights the important events of viral vector manufacturing between 2023 and 2025. For example, the New South Wales government in Australia pledged around US$90 million to build a viral vector facility at Westmead that will be dedicated to supporting academic research and clinical trials. Operations for the Westmead plant began in 2024, with its first clinical vector production scheduled for 2025.

Viral Vector Manufacturing Market Analysis — by Geography

Source: The Insight Partners Analysis

In Europe, Novartis opened its first dedicated viral vector production plant in Mengeš, Slovenia, in 2025. Named VIFA One, this fully automated facility supports cell and gene therapies for cancer and genetic diseases. This plant is part of a broader €3.5 billion (~US$3.8 billion) investment into biomanufacturing infrastructure in Slovenia.

Lonza Group AG; Merck KGaA; Thermo Fisher Scientific Inc.; Catalent Inc; Charles River Laboratories International Inc; WuXi AppTec Co Ltd; FUJIFILM Holdings Corp; GenScript Biotech Corporation; Takara Bio Inc; and Novartis AG are among the key players profiled in the viral vector manufacturing market report. Other players were also studied and analyzed during the market study to get a holistic view of the market and its ecosystem.

The report includes the viral vector manufacturing market forecast by type, disease indication, application, and end user. Based on type, the global viral vector manufacturing market is segmented into adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral vectors, and others. Adeno-associated viral vectors drive engagement and use of this type. Adeno-associated viral vectors (AAVs) have emerged as one of the most preferred platforms in gene therapy due to their excellent safety profile and long-term gene expression capabilities. AAVs are non-pathogenic, replication-defective viruses that require a helper virus (adenovirus) to replicate. These vectors can infect both dividing and non-dividing cells and exhibit low immunogenicity, making them suitable for systemic delivery and repeated dosing in certain cases. Although AAV vectors have a relatively small packaging capacity (~4.7 kb), their ability to provide sustained gene expression without integrating into the host genome—typically persisting as episomal DNA—is highly advantageous for treating chronic genetic disorders. AAVs have been used in several approved gene therapies, including Luxturna for inherited retinal disease and Zolgensma for spinal muscular atrophy, demonstrating their clinical utility. This segment held the largest viral vector manufacturing market share in 2024.

The scope of the viral vector manufacturing market report focuses on North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). Asia Pacific dominated the market in 2024, followed by North America and Europe.

The viral vector manufacturing market in Asia Pacific is segmented into Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific. India held the largest viral vector manufacturing market share in APAC. India's viral vector manufacturing sector is experiencing strong momentum in development, driven by increased investments and partnerships. One example is Bharat Biotech's launch of India's first synergistically integrated (Cell and Gene Therapy (CGT)) and viral production facility at Genome Valley, Hyderabad. The 50,000 sq ft facility has ~?648 crore (US$77 million) in investment and plans to produce human-grade vectors, including lentivirus and adeno-associated viruses (AAVs), for CGT applications. Bharat Biotech's experience with vaccine manufacturing should help facilitate an extension into regenerative and personalized therapies for disorders such as hemophilia and cancer.

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com